Skip to content
Startup Directory
Total raised
$3M
1 disclosed round
Latest round
Pre-Series A
Nov 2025 · $3M
Founded
2020
Headquarters
Delhi
Overview

About Crisprbits Private Limited

a. To manufacture, formulate, process, develop , refine all kinds of pharmaceuticals, antibiotics, medicinal preparations, drugs, chemicals, chemical products, dry salters, foods suitable for human, and allied goods and to carry on the business of chemists, druggists, importers, exporters, buyers, sellers, agents, distributors and stockists of all kinds of pharmaceuticals. b. To undertake all kinds of Research and Development in healthcare, biotechnology, pharmaceuticals and formulations not specifically covered aforesaid, and, in particular and without prejudice to the generality, to undertake clinical research, contract clinical research activities, bio-technology and services, to develop new products and provide support services for developing new products and substitutes for imported products and for manufacture and distribution of finished dosage forms and establishing pharmaceutical market networks. c. To manufacture, refine, purchase, sell, prepare, import, export all classes and kinds of drugs including pharmaceuticals preparations and formulations, fine chemicals, raw-materia

Momentum

Growth & Risk Signals

Momentum score
50 / 100
Trend
steady
Since last round
8 mo

Momentum is derived from funding recency, velocity, round count and scale.

Registry

Corporate Registry

Company class
Private
Paid-up capital
₹4 L
Authorized capital
₹10 L
Registrar
RoC-Delhi
Registered state
Delhi
CIN
U24110DL2020PTC371767

Manufacture of chemicals and chemical products

Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.

Capital

Funding Timeline

Total raised · $3M
Backers

Key Investors

3 across 1 round
Graph

Relationship Network

Explore in graph search →
Coverage

Articles about Crisprbits Private Limited

No articles linked to Crisprbits Private Limited yet. Editorial coverage will surface here automatically once tagged.